An Effort to Detect and Treat Alzheimer’s at Its Earliest Stages

Alzheimer’s disease begins decades before cognitive symptoms appear, driven by toxic alpha‑sheet oligomers that seed amyloid plaque formation. Valerie Daggett’s 30‑year research uncovered this unique protein structure, demonstrating that it is absent in normal proteins but pervasive across amyloid‑related disorders. By targeting the structural motif rather than traditional peptide sequences, Alpep aims to intervene at the earliest pathogenic stage, offering a potential disease‑modifying breakthrough that could shift the therapeutic paradigm from plaque removal to upstream oligomer neutralization.

Alpep’s SOBA (Soluble Oligomer Binding Assay) translates the structural insight into a blood‑based diagnostic. The assay uses synthetic alpha‑sheet peptides as capture agents, pulling down toxic oligomers with nanomolar affinity and then applying conventional antibodies to identify the specific disease protein. Validation studies suggest SOBA can flag oligomer presence up to 16 years before clinical onset, positioning it as a companion diagnostic for Alpep’s therapeutic pipeline. The test has achieved FDA breakthrough designation and is moving from a lab‑developed version toward an IVD‑cleared product, promising routine screening akin to cholesterol testing.

The therapeutic counterpart, SOBIN‑AD, employs intranasal delivery of a complementary synthetic peptide that binds and clears alpha‑sheet oligomers, stimulating microglial removal and preventing downstream plaque accumulation. Preclinical mouse models show reversal of cognitive deficits and reduced plaque burden even when treatment starts at mild‑cognitive‑impairment stages. Because the alpha‑sheet motif recurs in Parkinson’s, systemic amyloidosis, and over a dozen other protein‑misfolding diseases, Alpep’s platform could extend to a broad amyloid therapeutic class. Successful clinical translation would address a massive unmet market, offering early‑stage intervention and a unified biomarker‑driven approach across neurodegenerative disorders.